Introduction
It has long been assumed that blasts from T cell acute lymphoblastic leukemia (T-ALL) reflect the immunophenotypes of early stages of T cell differentiation. [1] [2] [3] Most T-ALL cases display phenotypes corresponding to various stages of thymocyte differentiation, which normally are not found in bone marrow (BM) or peripheral blood (PB). 4 The aberrant immunophenotypic characteristics of leukemic T lymphoblasts allow discrimination from T cell subsets in BM and thus can be used for detection of minimal residual disease (MRD). [5] [6] [7] [8] A comprehensive analysis of the immunophenotypic characteristics of T cells and the subsequent identification of all T cell subsets in normal BM are important for the reliable distinction between normal and leukemic T cells.
Previous studies in T-ALL strongly suggest that the use of multiparameter flow cytometry for the investigation of MRD can reach a high sensitivity and specificity for the identification of residual leukemic T lymphoblasts. [8] [9] [10] [11] A cooperative study conducted by six European centers involved in the BIOMED-1 Concerted Action 'Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation' applied multiparameter flow cytometry in which triple antibody combinations were used together with sensitive data acquisition methods (such as 'live gate' acquisition). Using this approach we obtained detailed information on cell subsets that are present in normal BM at very low frequencies and that may remain undetected using conventional methods of analysis.
The immunophenotyping methods (staining protocols and flow cytometry) were carefully standardized in order to develop a highly reproducible and sensitive approach to identify both major and minor subsets of T cells present in BM and their relative distribution according to age. Once normal T cell subsets were identified, we focused our attention on the 'empty spaces' left in multidimensional flow cytometry dot plots of each studied antigen combination, as has previously been reported for precursor B cells. [12] [13] [14] Subsequently, we used the same triple antibody combinations and flow cytometry protocols to analyze 65 consecutive T-ALL cases diagnosed in the six participating laboratories. Our aim was to assess the incidence of aberrant phenotypes, which can be used for the follow-up of MRD in T-ALL patients.
Materials and methods

Specimen collection Normal BM samples:
Normal BM samples (n = 35) were obtained from healthy donors (n = 29) and patients with idiopathic thrombocytopenia (ITP) (n = 6), recruited in the six European centers involved in the BIOMED-1 Concerted Action on MRD. The following centers participated: Portuguese Institute of Oncology, Lisbon, Portugal; Karolinska Hospital, Stockholm, Sweden; University of Salamanca, Salamanca, Spain; Department of Immunology, Erasmus University, Rotterdam and University Hospital, Rotterdam, The Netherlands; Dutch Childhood Leukemia Study Group, The Hague, The Netherlands; and M Tettamanti Research Center, Monza, Italy.
Informed consent was obtained from all donors or parents in cases of children less than 15 years old in accordance with local Medical Ethics Committees. The samples from patients with ITP were obtained for diagnostic purposes. The median age of the donors was 15 years, ranging from 2 to 75 years 817 old (mean age 24), the male/female ratio was 0.8. Moreover, 16 follow-up BM samples from children receiving chemotherapy for B-precursor ALL were included to investigate if T cell content and distribution changed during cytostatic treatment.
Leukemic samples:
T-ALL samples (n = 65) were obtained in the participating centers for diagnostic purposes. The morphological diagnosis of ALL was made on the basis of microscopic investigation of May-Grü nwald-Giemsa stained BM smears. The immunologic diagnosis of T-ALL was made according to well-established criteria. 4 The median age of the patients was 13 years, ranging from 1 to 52 years (mean 16), and the male/female ratio was 1.8.
Sample preparation
Bone marrow aspirates were collected in either heparin or EDTA anticoagulant and maintained at room temperature (RT) until processed (not longer than 24 h). The nucleated cell count was adjusted to 1-2 × 10 7 cells/ml. For sample preparation, a stain and then lyse/wash technique was used. Briefly, 100 l of BM cell suspension (at least 1 × 10 6 nucleated cells) were incubated for 10-15 min (RT, in the dark) with saturating amounts of five different triple combinations of monoclonal antibodies (Mab, Table 1 ). After incubation, 2 ml of FACS lysing solution (Becton Dickinson (BD), San Jose, CA, USA) diluted 1/10 in distilled water was added and samples were incubated for another 10 min at RT in the dark. Subsequently, cells were washed and re-suspended in 1 ml of PBS.
Cytoplasmic (cy)CD3 and nuclear terminal deoxynucleotidyl transferase (TdT) were detected after staining for surface markers (as above), and fixation/permeabilization with Permeafix (OPM; Ortho, Raritan, NY, USA) or Fix & Perm (F/P; An der Grub, Vienna, Austria). 15 The reagents were used following the manufacturer's recommendations. After OPM fixation and during permeabilization with F/P, the cells were incubated with anti-TdT or CD3 Mab (30 or 15 min, respectively) then washed and resuspended in PBS. Previous comparative 
Data acquisition and analysis
Data acquisition was performed in all centers in a standardized manner, using FACScan flow-cytometers (BD), equipped with either LysisII or CellQuest (BD) software programs. Instrument set-up and calibration was performed in a standardized way as previously described. 12 For the analysis of normal BM samples, a two-step acquisition procedure was used. First, 15 × 10 3 non-gated events were acquired from the BM samples. For all leukemic samples, 15 × 10 3 events were acquired from the total BM and, whenever appropriate, the expression of various markers analyzed after gating focused on the leukemic blast cells. The fluorescence intensity of T cell markers observed in normal T-lymphocytes present in each analyzed sample was used as the reference value for describing the intensity of antigen expression in leukemic blasts.
Standardization of the procedures and quality control
Prior to the study, all procedures used for the immunophenotypic analysis of the normal compartment of the CD7 + BM cells were standardized among the six participating centers via collaboration in experimental work and regular laboratory meetings. The same antibody clones, fluorochrome conjugates, and triple-staining combinations were used throughout the study in all six participating laboratories. The agreed antibody combinations were those providing the most powerful discrimination between the T cell subsets under study. Procedures for instrument set-up and calibration were carefully compared and one common well-standardized method was selected. The light scatter characteristics and the autofluorescence levels of normal PB lymphocytes were used as reference values for instrument settings. As described above, the same two-step acquisition procedure was used in all lab- Table 2 Frequency of various T cell subsets present in normal bone marrow oratories and data analysis was performed with Paint-a-Gate Pro (BD) software. A special meeting for personnel of all participating centers was devoted to the training in calibration, instrument settings, and data acquisition and analysis.
Quality control of the procedures was performed both prior to and during the study. For this purpose, triple staining of a normal PB samples for CD3-FITC (Leu4, BD)/CD4-PE (Leu3, BD)/CD8-PE/Cy5 (CD8-TRI, Caltag Laboratories) was performed daily. Finally, the data were centrally re-analyzed at Karolinska Hospital. Statistical analysis (see below) did not show any significant differences in data obtained at different laboratories.
Statistical analysis
All the results are expressed as mean with one standard deviation (s.d.). Correlation between antigen expression and the age of the control BM donors was investigated using t-test and Pearson correlation test. In order to assess the statistical significance of the differences observed between results from various groups, the analysis of variance (ANOVA) was used. P values less than 0.05 were considered to be statistically significant.
Results
Expression patterns of T cell markers in normal bone marrow
The mean frequency of CD7 + cells in BM was 10% ± 3.6% (range 5.2-20.4%). The proportion of CD7 + cells increased with age: 7.9% ± 1.8% in children under 14 vs 14.1% ± 3.8% in healthy donors 14 or more years of age (P Ͻ 0.01). No significant differences between the six participating centers were found regarding the frequency of CD7 + BM cells (P Ͼ 0.05).
Expression patterns of the various T cell marker combinations analyzed within the CD7 + BM cells are exemplified in Figure 1 and their overall frequencies (expressed both as percentages of CD7 + cells and of total BM cells) are shown in Table 2 .
No clearly defined populations of CD34 + /CD7 + and TdT
+ cells were found in any of the normal BM samples analyzed. This was true both when 'live gate' acquisition was performed on the basis of CD7 expression and for TdT + or CD34 + cells. Thus, we can assume that frequencies of these cells in normal BM were less than 1 in 10 4 cells in 20 studied samples.
As shown in Figure 1a , CD7/CD5/CD3 triple staining (I) showed the existence of four distinct CD7 + subsets in BM, the CD3 + /CD5 + subset being dominant (84%); other subsets included CD3 
/CD5
− subpopulation expressed as a percentage of total CD7
+ cells increased with age (correlation coefficient (corr coeff) 0.4361, P = 0.01). However, no significant correlation was found when CD5
+ cells were expressed as a percentage of the total number of BM cells. No significant differences were found in the distribution of the other subsets according to age or between participating centers (P Ͼ 0.05).
Using the CD7/CD4/CD8 triple combination (II), six subsets of CD7 + cells were identified ( Figure 1b , Table 2 ure 1b, Table 2 ). In these minor subsets, expression of CD4 was always either higher or lower than CD8 and both antigens never showed similar intensity of expression (when CD4 was 'bright', the CD8 was 'dim' and vice versa). The proportion of the CD4 + cells and as a percentage of total BM cells. No significant differences were found in the frequency of the various T cell subsets between the six participating centers, P Ͻ 0.05.
The subsets identified by the CD7/CD2/CD3 staining, were analyzed separately for CD3 + (III) (two subsets defined, Figure  1c ) and CD3 − (IV) cells (three subsets defined, Figure 1d ), (Table 2) . No significant differences were found regarding the distribution of these subsets according to age or between participating centers. Further studies have shown that almost all cells in the CD7
− population expressed the CD56 NK-cell associated marker (98% ± 1%).
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Leukemia should be noted that the intensity of expression of both myeloid-associated markers was 'dim' in all samples. The total numbers and distribution of various T cell subsets remained stable during chemotherapy. Table 3 shows the results obtained in 16 patients with B precursor ALL tested at various phases of treatment. No significant differences were found between the patients and healthy donors. No populations of C7/CD34 or cyCD3/TdT cells were found in these patients.
Immunophenotypic patterns of T-ALL blast cells
Based on the findings obtained from the analysis of normal BM samples, we established the potential patterns of aberrant antigen expression in T-ALL. These aberrant patterns are defined by their position in the so-called 'empty spaces' found on the multidimensional dot plots of normal BM samples (Figure 2) . Based upon the 'empty space' definition, we found that all 65 investigated T-ALL cases showed aberrant immunophenotypes. The frequencies of each of the various aberrant phenotypic patterns are given in Table 4 , and several aberrant patterns are exemplified in Figure 2 . In most of the cases more than one aberration was found: 91% of cases had aberrant phenotypes in at least two triple stains, 65% in at least three, 25% in at least four, and 4% of cases were aberrant in all five antibody combinations. Table 5 shows a detailed description of the different aberrant phenotypes found in the 65 T-ALL cases included in the present study. The most common aberrant pattern was the co-existence of the TdT together with CD7 and/or cyCD3, found in 58 of the 64 studied cases (91%). Co-expression of CD34 with CD7 and other surface T cell-associated antigens was found in 40% of all T-ALL cases analyzed (23/58). In 36 of 65 cases (55%), a bright expression of CD7 (as compared to normal T-lymphocytes) was noted. In nine of 65 cases (14%) the intensity of CD7 expression was higher than in normal NK cells, and one of these cases co-expressed CD56.
Based on these findings, the most common leukemia associated phenotype was an ectopic (thymus associated) antigen expression (91%). Additionally, asynchronous antigen expression and rare phenotypes were found in 40% and 72% of cases, respectively. With regard to cross-lineage antigen expression, none of the analyzed T-ALL cases expressed the CD19 B cell-associated marker. 'Dim' expression of the myeloid-associated markers CD13 and CD33 was detected in eight of 58 (16%) and six of 58 (10.5%) cases, respectively (four of these showed both markers). Totally, based on the analysis of myeloid and NK cell-associated markers, only 13.5% of the T-ALL cases showed an aberrant immunophenotype.
Discussion
The CD7 antigen has been classically considered the earliest T cell-associated marker expressed during maturation of T-lymphocytes. This is based on the presence of CD45
− cells in human fetal liver at the gestational age of 7 weeks at which the thymic rudiment is colonized by T cell progenitors. 16 More recent findings have shown that human multi-potent progenitor cells expressing CD34 have the capacity to differentiate into T cells once they are placed in the thymic environment. 17 Differentiating CD34
+ bone marrow cells that co-express CD7 and display poor ability to mature into the myeloid lineage can also efficiently give rise to T cells in culture systems with cytokines (interleukin 7). 18 These lymphoid committed precursors might be the true thymic repopulating cells. In the thymus, cells with a similar CD34 +
CD7
+ phenotype include the most primitive thymocyte precursors. CD34
+ thymocytes have no ability to differentiate into myeloid cells, but may include NK cell precursors. 19, 20 In spite of these findings, it is still controversial whether commitment to the T cell lineage occurs in man before or after T cell precursors migrate into the thymus.
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CD7 expression is then retained until the last stages of both T and NK cell differentiation. 22, 23 The vast majority of T-ALL cases also express the CD7 antigen. [2] [3] [4] 24 Based on these observations, we have focused our studies on T cell subsets in the CD7 + lymphoid population of normal BM. We have a Results are expressed as numbers of cases and percentages. Normal patterns of expression are shown in Figure 1 and Table 2 , aberrant patterns in Figure 2 . used a double-step acquisition strategy in which information on CD7 + events was selectively obtained. This strategy was successfully applied for identification of aberrant cells in follow-up samples of patients included in this study as exemplified in Figure 3 . There were no CD7 negative cases in our material. An alternative approach for blast cell gating strategies in CD7 negative or CD7 dim cases would be the use of other T cell markers as cyCD3 or CD2 or CD5 (Figure 3b ).
Since the results were derived from six different laboratories, our first aim was to standardize the techniques and to compare the results in order to avoid variations due to inconsistencies in methodology or data analysis. Antibodies, sample preparation, staining methods, instrument settings, data acquisition and data analysis were standardized prior to the immunophenotyping of the normal BM and T-ALL samples. Identical results were obtained in each individual center as reflected both by the localization of the different cell populations in the dot plot diagrams and the absence of statistically significant differences in the percentages of each subset analyzed. Statistical analysis confirmed the lack of significant inter-laboratory variation of results.
We [25] [26] [27] Sorting of human BM CD34 + cells showed that the CD34
+ /CD2 − phenotype correlated with the transcription of CD3 but not CD3␥ or CD3␦ (a pattern of CD3 gene transcription observed in mature blood NK cells but not in T cells). 27 In contrast to the above-mentioned studies, our results show that the frequencies of CD34 + /CD7 + cells and 
/CD7
+ phenotypes, especially if co-expressed together with cyCD3 and/or TdT at frequencies higher than 10 −4 can be considered as leukemia associated.
Most T-ALL in our series (91%) co-expressed TdT and cyCD3 and/or CD7. This makes the TdT/CD7/cyCD3 triple labeling a powerful and broadly applicable tool for MRD studies, in accordance with previous early reports. 25, 28 Twentythree of 58 analyzed T-ALL cases (40%) co-expressed CD34 and CD7. It should be noted that in most CD34 + T-ALL cases the expression of this marker was only seen on a subset of the CD7 + leukemic blast cells. In the CD7/CD38/CD34 labeling, the information provided by CD38 was marginal, thus limiting the use of this triple antigen combination for MRD studies.
The most informative of the other marker combinations was
Leukemia the CD7/CD2/CD3 triple staining (75% aberrant cases) followed by the CD7/CD5/CD3 staining (58% aberrant cases). Aberrant phenotypes were also detected in 38% of T-ALL cases analyzed with the CD7/CD4/CD8 triple staining. Thus, the combined use of only a few common triple stains would allow the flow cytometric follow-up of leukemic cells in all T-ALL cases. Our results are in agreement with previously reported data on the incidence of aberrant phenotypes in T-ALL. 6, 8, 9 In most T-ALL cases three or more aberrant immunophenotypic patterns were found, mainly reflecting ectopic thymic phenotypes. The most frequent ectopic phenotype was characterized by either dim or absent surface CD3 expression and double expression of cyCD3/TdT. 28 In seven of 65 studied T-ALL cases (10.7%) leukemic blasts were CD3 + thymocytes. These ectopic thymic immunophenotypes are found neither in normal BM nor in PB of ALL patients during and after treatment. 29 By comparison to normal BM, T and NK cells, aberrant (low or high) antigen expression was detected in 60% of the cases and was usually related to the dim expression of CD3, CD5 or CD2. Over-expression of CD7 was detected in 14% of the cases and abnormally low expression of CD7 or CD5 was detected in six (9%) and 29 (45%) of the cases, respectively.
Our results show that only 12% of analyzed cases were CD13 and/or CD33 positive. We have taken into account only cases with strong expression of the myeloid markers on T cell blasts that could be used for MRD investigation. This may explain the relatively low incidence found in the present study using sensitive CD33-PE and CD13-PE conjugates, as compared to some other reports in the literature. 11, [30] [31] [32] [33] It is obvious from our study that the immunophenotypes of T-ALL differ significantly from normal BM T cells and NK cells. For a major part this is caused by their thymocyte origin (see ectopic antigen expression, Table 5 ). However, the neoplastic transformation might also have affected antigen expression patterns (Table 5) , as has been previously observed in B precursor ALL 34, 35 and in acute myeloid leukemia. 36, 37 Furthermore, it should be noted that T-ALL also differ from each other displaying unique immunophenotypic patterns. In summary, our results show that the use of only five triple marker combinations allows detection of ectopic thymic phenotypes in all T-ALL cases. In addition, standardization of the methods for cell staining, instrument calibration, data acquisition and data analysis provides an objective and reproducible basis for application of flow cytometric MRD detection in T-ALL patients. In this way, flow cytometric MRD detection provides a relatively inexpensive and rapid alternative to PCR-based MRD detection via rearranged immunoglobulin or T cell receptor genes. 6, 8, 10, 38 
